WuXi AppTec
Search results
Jul 19, 2022 · Singapore, July 19, 2022 – WuXi Biologics (“WuXi Bio”) (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced a 10-year USD$1.4 billion (S$2 billion) investment plan to expand the company’s research, development, and large-scale drug substance and drug product (DS/DP ...
Mar 19, 2024 · Singapore, March 19, 2024 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has broken ground on its new 13.5-hectare CRDMO center in Tuas Biomedical Park, Singapore.
Mar 19, 2024 · WuXi Biologics announced a USD$1.4 billion (S$2 billion) investment in Singapore in 2022. The CRDMO center will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing solutions upon completion.
Jul 21, 2022 · SINGAPORE - Chinese companies WuXi Biologics and WuXi AppTec will be investing up to $4 billion in total in Singapore to grow their research and development (R&D) and manufacturing capabilities...
Jul 21, 2022 · WuXi Bio is laying out $1.4 billion over the next 10 years to beef up research and development plus large-scale drug substance and drug product manufacturing in Singapore. The upgrade is...
Jul 19, 2022 · WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore. This investment will establish a cutting-edge, fully integrated CRDMO center in Singapore, including a research and...
May 17, 2024 · WuXi Biologics announced in July 2022 to invest S$2bn ($1.4bn) over ten years to expand R&D services and augment large-scale drug substance and drug product manufacturing capacities and capabilities in Singapore.
